In patients with COVID-19, increased concentrations of Ang II, a potent vasoconstrictor agent, result in increased tissue factor (TF) and plasminogen activator inhibitor-1 (PAI), contributing to the hypercoagulable state (Miesbach and Makris, 2020[49]). This evidence concerns the gene TF and COVID-19.